Peritoneal dialysis (PD)-related peritonitis is one of the most important factors affecting the long-term success of PD. Adrenal insufficiency is a clinical manifestation of inadequate production of glucocorticoids with accompanying deficiency of mineralocorticoids and adrenal androgens. We present a 58-year-old PD patient who admitted to hospital with fever, abdominal pain, vomiting, and confusion. The patient was treated with cephazolin and ceftazidime after the confirmation of peritonitis. Despite the resolution of peritonitis after 2 weeks with appropriate antibiotic treatment, the patient continued to suffer from vomiting, hypotension, and confusion. After the evaluation of basal serum cortisol and 250 µg ACTH stimulation test, the patient had been diagnosed as adrenal insufficiency and treated with fludrocortisone 0.1 mg/day. Patients remaining vomiting, hypotension, and confusion symptoms were corrected after the fludrocortisone therapy. Following 2 months of successful treatment of adrenal insufficiency, the patient had adherence problem with fludrocortisone for 3–4 weeks. On an outpatient visit, serum ACTH and cortisol levels were normal despite the discontinuation of fludrocortisone and so the patient had been evaluated as partial adrenal insufficiency secondary to PD-related peritonitis. In conclusion, adrenal insufficiency should be kept in mind in PD patients suffering from hypotension and peritonitis.

1.
Salzer WL. Peritoneal dialysis-related peritonitis: challenges and solutions.
Int J Nephrol Renovasc Dis
. 2018 Jun;11:173–86.
2.
Chabre O, Goichot B, Zenaty D, Bertherat J. Group 1. Epidemiology of primary and secondary adrenal insufficiency: prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality.
Ann Endocrinol (Paris)
. 2017 Dec;78(6):490–4.
3.
Shetty A, Afthentopoulos IE, Oreopoulos DG. Hypotension on continuous ambulatory peritoneal dialysis.
Clin Nephrol
. 1996 Jun;45(6):390–7.
4.
Khanna R, Wu G, Vas SI, Digenis G, Oreopoulos DG. Update on continuous ambulatory peritoneal dialysis.
Ric Clin Lab
. 1983 Oct-Dec;13(4):381–95.
5.
Malliara M, Passadakis P, Panagoutsos S, Theodoridis M, Thodis E, Bargman J, et al. Hypotension in patients on chronic peritoneal dialysis: etiology, management, and outcome.
Adv Perit Dial
. 2002;18:49–54.
6.
Seo Y, Jeung S, Kang SM, Yang WS, Kim H, Kim SB. Use of fludrocortisone for intradialytic hypotension.
Kidney Res Clin Pract
. 2018 Mar;37(1):85–8.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.